Clinical Trials

Encouraging immune response seen in "Prime/Boost" phase I HIV vaccine study

Published in Vaccine Weekly, October 5th, 2005

GenVec, Inc., (GNVC) announced that preliminary safety and immune response data in a limited sample size of eight healthy volunteers enrolled in one of several ongoing phase I clinical trials involving an HIV vaccine candidate showed that the vaccine regimen combining DNA priming and adenovector boosting was well-tolerated and produced a vigorous cellular and antibody immune response.

The HIV vaccine candidate was developed by GenVec and the Vaccine Research Center (VRC) of the U.S. National Institute of Allergy and Infectious Diseases(NIAID), U.S. National Institutes of Health.

These preliminary findings were presented at the AIDS Vaccine 2005...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2005-10-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry